Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3765150
Max Phase: Preclinical
Molecular Formula: C40H62N6O8
Molecular Weight: 754.97
Molecule Type: Small molecule
Associated Items:
ID: ALA3765150
Max Phase: Preclinical
Molecular Formula: C40H62N6O8
Molecular Weight: 754.97
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCC/C=C/C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@H]1COC(=O)[C@@H]2C[C@@H](C)CN2C(=O)[C@H](CC)NC(=O)[C@@H]2CCCCN2C(=O)[C@@H]2CCCN2C1=O
Standard InChI: InChI=1S/C40H62N6O8/c1-4-6-7-11-19-34(47)41-29(23-27-15-9-8-10-16-27)35(48)43-30-25-54-40(53)33-22-26(3)24-46(33)37(50)28(5-2)42-36(49)31-17-12-13-20-44(31)39(52)32-18-14-21-45(32)38(30)51/h11,19,26-33H,4-10,12-18,20-25H2,1-3H3,(H,41,47)(H,42,49)(H,43,48)/b19-11+/t26-,28+,29+,30+,31+,32+,33+/m1/s1
Standard InChI Key: JRYLTOAJHCNAKK-ZJIZBMKYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 754.97 | Molecular Weight (Monoisotopic): 754.4629 | AlogP: 2.73 | #Rotatable Bonds: 10 |
Polar Surface Area: 174.53 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 14 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.14 | CX Basic pKa: | CX LogP: 2.93 | CX LogD: 2.93 |
Aromatic Rings: 0 | Heavy Atoms: 54 | QED Weighted: 0.17 | Np Likeness Score: 0.64 |
1. Goodreid JD, Janetzko J, Santa Maria JP, Wong KS, Leung E, Eger BT, Bryson S, Pai EF, Gray-Owen SD, Walker S, Houry WA, Batey RA.. (2016) Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity., 59 (2): [PMID:26818454] [10.1021/acs.jmedchem.5b01451] |
Source(1):